News
09-26-2011, 04:00 AM
Laurantis Pharma, a privately held biotechnology company based in Finland, today announced that Lymfactin, adenoviral VEGF-C growth factor therapy, was successful in rebuilding lymphatic vessels in pre-clinical animal models.
More... (http://www.news-medical.net/news/20110926/Laurantis-Pharmas-Lymfactin-rebuilds-lymphatic-vessels-in-pre-clinical-animal-models.aspx)
More... (http://www.news-medical.net/news/20110926/Laurantis-Pharmas-Lymfactin-rebuilds-lymphatic-vessels-in-pre-clinical-animal-models.aspx)